CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MaxCyte Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MaxCyte Inc
9713 KEY WEST AVENUE, SUITE 400
Phone: (301) 517-5556p:301 517-5556 ROCKVILLE, MD  20850  United States Ticker: MXCTMXCT
Business Summary
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes-Yes-

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
3826 Laboratory analytical instruments
7372 Prepackaged software
7374 Computer processing and data preparation and processing services

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Richard H.Douglas 71 11/3/2021 1/1/2018
President, Chief Executive Officer, Director MaherMasoud 49 1/1/2024 1/1/2020
Chief Financial Officer Douglas J.Swirsky 54 3/27/2023 3/27/2023
7 additional Officers and Directors records available in full report.

Business Names
Business Name
CARMA Cell Therapies, Inc.
CCTI, Inc.
MXCN
MXCR
MXCT

General Information
Number of Employees: 143 (As of 12/31/2023)
Outstanding Shares: 105,482,558 (As of 11/1/2024)
Shareholders: 35
Stock Exchange: NASD
Federal Tax Id: 522210438
Fax Number: (301) 944-1703
Email Address: info@maxcyte.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024